Farnesyltransferase inhibitor as anticancer agent

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 638-652

  Agrawal, Anuj G ^a   Somani, Rakesh R ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

Farnesyltransferase; Farnesyltransferase inhibitor; Ras protein

Indexed keywords

(ALPHA HYDROXYFARNESYL)PHOSPHONIC ACID; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE) 1 (4 PYRIDYLACETYL)PIPERIDINE; ANTINEOPLASTIC AGENT; BMS 186511; CISPLATIN; FARNESYL DIPHOSPHATE; FLUOROURACIL; FOLINIC ACID; FUSIDIENOL; GEMCITABINE; GLIOTOXIN; IMATINIB; IRINOTECAN; L 778123; LONAFARNIB; MANUMYCIN; MELPHALAN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; NATURAL PRODUCT; PACLITAXEL; PLACEBO; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TAXANE DERIVATIVE; TETRAPEPTIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE PANCREATITIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON TUMOR; COLORECTAL CANCER; CONFUSION; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG ANALYSIS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DYSPNEA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL TOXICITY; GENE MUTATION; GLIOMA; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; LARYNX CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MELANOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN FUNCTION; PROTEIN PROCESSING; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; VOMITING; ANIMAL; CHEMISTRY; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RAS PROTEINS;

EID: 69249215282     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788452702     Document Type: Article

References (142)

1. Brunton, L.L.; Lazo, J.S.; Parker, K.L. Goodman and Gilman's "The Pharmacological Basis of Therapeutics," McGraw-Hill Medical Publishing Division: New York, 2006.
2. Block, J.H.; Beale, J.M. Wilson and Gisvold's "Text book of Organic, Medicinal and Pharmaceutical Chemistry," Lippincott-Raven Publisher: New York, 2004.
3. Gridelli, C.; Rossi, A.; Maione, P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene, 2003, 22, 6629-38.
4. Minna, J.D.; Gazdar, A.F.; Sprang, S.R.; Herz, J. Cancer: A bull's eye for targeted lung cancer therapy. Science, 2004, 304, 1458-61.
5. Hochhaus, A. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Ann. Hematol., 2004, 83 (Suppl.1), S65-S66.
6. Bos, J.L. Ras oncogenes in human cancer: a review. Cancer Res., 1989, 49, 4682-4689.
7. Bollag, G.; McCormick, F. Regulators and effectors of ras proteins. Ann. Rev. Cell Bio., 1991, l7, 601-632.
8. Barbacid, M. Ras genes. Ann. Rev. Biochem., 1987, 56, 779-827.
9. Boguski; M.S.; McCormick, F. Proteins regulating Ras and its relatives. Nature, 1993, 366, 643-54.
10. Lowy, D.R.; Willumsen, B.M. Function and regulation of Ras. Ann. Rev. Biochem., 1993, 62, 851-891.
11. Leonard, D.M. Ras farnesyltransferase: A new therapeutic target. J. Med. Chem., 1997, 40, 2971-90.
12. Ellis, R.W.; Defeo, D.; Shih, T.Y.; Gonda, M.A.; Young, H.A.; Tsuchida, N.; Lowy, D.R.; Scolnick, E.M. The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature, 1981, 292, 506-11.
13. Ruta, M.; Wolford, R.; Dhar, R.; Defeo-Johnson, D.; Ellis, R.W.; Scolnick, E.M. Nucleotide sequence of the two rat cellular H-ras genes. Mol. Cell Bio., 1986, l6, 1706-10.
14. Shimizu, K.; Goldfarb, M.; Suard, Y.; Perucho, M.; Li, Y.; Kamata, T.; Feramisco, J.; Stavnezer, E.; Fogh, J.; Wigler, M.H. Three human transforming genes are related to the viral oncogenes. Proc. Natl. Acad. Sci. USA, 1983, 80, 2112-16.
15. Morgillo, F.; Lee, H. Development of farnesyl transferase inhibitors as anticancer agents: current status and future. Cancer Ther., 2007, 5, 11-18.
16. Roberts, P.J.; Mitin, N.; Keller, P.J.; Chenette, E.J.; Madigan, J.P.; Currin, R.O.; Cox, A.D.; Wilson, O.; Kirschmeier, P.; Der, C.J. Rho family GTPase modification and dependence on CAAX motifsignaled post translational modification. J. Biol. Chem., 2008, 283(37), 25150-163.
17. Epifano, F.; Curini, M.; Genovese, S.; Blaskovich, M.; Hamiltonc, A.; Sebtic, S.M. Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I. Bioorg. Med. Chem., 2007, 17, 2639-42.
18. Rowinsky, E. K. Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J. Clin. Oncol., 2006, 24(19), 2981-84.
19. McCormack, F. Activators and effectors of Ras p21 proteins. Curr. Opin. Genet. Dev., 1994, 4, 71-76.
20. Gibbs, J.B. GTPases in Biology, Springer-Verlag: New York, 1993.
21. Hancock, J.F.; Magee, A.I.; Childs, J.E.; Marshall, C. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell, 1989, 57, 1167-77.
22. Hancock, J.F.; Paterson, H.; Marshall, C.J. A polybasic domain or palmitoylation is required for the addition of the CAAX motif to localize p21 to the plasma membrane. Cell, 1990, 63, 133-39.
23. Jackson, J.H.; Cochrane, C.G.; Bourne, J.R.; Solski, P.A.; Buss, J.E.; Der, C.J. Farnesyl modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA, 1990, 87, 3042-46.
24. Lowry, D.R.; Willumsen, B.M. Function and regulation of Ras. Ann. Rev. Biochem., 1993, 62, 851-91.
25. Shih, C.; Weinberg, R.A. Isolation of transforming sequence from a human bladder carcinoma cell line. Cell, 1982, 29, 161-69.
26. Krontiris, T.; Cooper, G.M. Transforming activity in human tumor DNAs. Proc. Natl. Acad. Sci. USA, 1981, 78, 1181-84.
27. Perucho, M.; Goldfarb, M.; Shimizu, K.; Lama, C.; Fogh, J.; Wigler, M. Human tumor derived cell lines contain common and different transforming genes. Cell, 1981, 27, 467-476.
28. Khosravi-Far, R.; Der, C.J. The Ras signal transduction pathway. Cancer Metastasis Rev., 1994, 13, 67-89.
29. Widemann, B.C.; Salzer, W.L.; Arceci, R.J.; Blaney, S.M.; Fox, E.; End, D.; Gillespie, A.; Whitcomb, P.; Palumbo, J.S.; Pitney, A.; Jayaprakash, N.; Zannikos, P.; Balis, F.M. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J. Clin. Oncol., 2006, 24(3), 507-16.
30. Clark, G.J.; Der, C.J. In Cellular cancer; Markers, C.T.; Garret, T.; Sell, S. Ed.; Humana Press: Totowa, NJ, 1995, pp 17-52.
31. Beaupre, D.M.; Kurzrock, R. Ras and leukemia: From basic mechanisms to gene-directed therapy. J. Clin. Oncol., 1999, 17, 1071-79.
32. Kato, K.; Cox, A.D.; Hisaka, M.M.; Graham, S.M.; Bus, J.E.; Der, C.J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA, 1992, 89, 6403-407.
33. McCormick, F. How receptors turn Ras on. Nature, 1993, 363, 15-17.
34. Casey, P.J. p21 Ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA, 1989, 86, 8323-8327.
35. Gelb, M.H. Protein prenylation, et cetera: Signal transduction in two dimensions. Science, 1997, 275, 1750-51.
36. Cox, A.D.; Der, C.J. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras? Biochim. Biophys. Acta., 1997, 1333, F51-F71.
37. Omer, C.A.; Anthony, N.J.; Buser-Doepner, C.A.; Burkhardt, A.L.; deSolms, S.J.; Dinsmore, C.J.; Gibbs, J.B.; Hartman, G.D.; Koblan, K.S.; Lobell, R.B.; Oliff, A.; Williams, T.M.; Kohl, N.E. Farnesyl: Protein transferase inhibitors as agents to inhibit tumor growth. Biofactors, 1997, 6, 359-66.
38. Gibbs, J.B.; Oliff, A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Ann. Rev. Pharmacol. Toxicol., 1997, 37, 143-66.
39. Yamane, H.K.; Farnsworth, C.C.; Xie, H.Y.; Howald, W.; Fung, B.K.; Clarke, S.; Gelb, M.H.; Glomset, J.A. Brain G protein gamma subunits contain all-trans-geranylgeranylcysteine methyl ester at their carboxyl termini. Proc. Natl. Acad. Sci. USA, 1990, 87, 5868-72.
40. Schafer, W.R.; Kim, R.; Sterne, R.; Thorner, J.; Kim, S.; Rine, J. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science, 1989, 245, 379-85.
41. Casey, P.J.; Seabra, M.C. Protein prenyltransferases. J. Biol. Chem., 1996, 271, 5289-5292.
42. James, G.L.; Goldstein, J.L.; Brown, M.S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetics in vitro. J. Biol. Chem., 1995, 266, 14603-610.
43. Armstrong, S.A.; Hannah, V.C.; Goldstein, J.L.; Brown, M.S. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J. Biol. Chem., 1995, 270, 7864-68.
44. Marks, R.E.; Ho, A.W.; Robbel, C.; Kuna, T.; Berk, S.; Gajewski, T.F. Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood, 2007, 110, 1982-88.
45. Subramanian, T.; Liu, S.; Troutman, J.M.; Andres, D.A.; Spielmann, H.P. Protein farnesyltransferase-catalyzed isoprenoid transfer to peptide depends on lipid size and shape, not hydrophobicity. Chembiochem., 2008, 9(17), 2872-82.
46. Zhang, F.L.; Casey, P.J. Protein prenylation: Molecular mechanisms and functional consequences. Ann. Rev. Biochem., 1996, 65, 241-69.
47. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Farnesyltransferase inhibitors: A detailed chemical view on an elusive biological problem. Curr. Med. Chem., 2008, 15(15), 1478-92.
48. Moomaw, J.F.; Casey, P.J. Mammalian protein geranylgeranyltransferase-subunit composition and metal requirements. J. Biol. Chem., 1992, 267, 17438-43.
49. Moores, S.L.; Schaber, M.D.; Mosser, S.D.; Rands, E.; O'Hara, M.B.; Garsky, V.M.; Marshall, M.S.; Pompliano, D.L.; Gibbs, J.B. Sequence dependence of protein isoprenylation. J. Biol. Chem., 1991, 266, 14603-10.
50. Reiss, Y.; Goldstein, J.L.; Seabra, M.C.; Casey, P.J.; Brown, M.S. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell, 1990, 62, 81-88.
51. Reiss, Y.; Stradley, S.J.; Gierasch, L.M.; Brown, M.S.; Goldstein, J.L. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA, 1991, 88, 732-36.
52. Park, H.W.; Boduouri, S.R.; Moomaw, J.F.; Casey, P.J.; Beese, L.S. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science, 1997, 275, 1800-804.
53. Andres, D.A.; Goldstein, J.L.; Ho, Y.K.; Brown, M.S. Mutational analysis of alpha-subunit of protein farnesyltransferase: Evidence for a catalytic role. J. Biol. Chem., 1993, 268, 1383-90.
54. Kumar, A.; Beresini, M.H.; Dhawan, P.; Mehta, K.D. Alphasubunit of farnesyltransferase is phosphorylated in vivo: Effect of protein phosphatase-1 on enzymatic activity. Biochem. Biophys. Res. Commun., 1996, 222, 445-52.
55. Tshantz, W.R.; Furfine, E.S.; Casey, P.J. Substrate binding is required for release of product form mammalian protein farnesyltransferase. J. Biol. Chem., 1997, 272, 9989-93.
56. Furfine, E.S.; Leban, J.J.; Landavazo, A.; Moomaw, J.F.; Casey, P. J. Protein farnesyl transferase-kinetic of farnesyl pyrophosphate binding and product release. Biochemistry, 1995, 34, 6857-62.
57. Sebti, S.M.; Hamilton, A.D. New approaches to anticancer drug design based on the inhibition of farnesyltransferase. Drug Discov. Today, 1998, 3, 26-33.
58. Heimbrook, D.C.; Oliff, A. Therapeutic intervention and signaling. Curr. Opin. Cell Biol., 1998, 10, 284-88.
59. Kohl, N.E. Farnesyltransferase inhibitors: preclinical development. Ann. N. Y. Acad. Sci., 1999, 886, 91-102.
60. Pan, J.; Song, E.; Cheng, C.; Lee, M.H.; Yeung, S.C. Farnesyltransferase inhibitors-induced autophagy: alternative mechanisms? Autophagy, 2009, 5(1), 129-31.
61. Feldkamp, M.M.; Lau, N.; Roncari, L.; Guha, A. Isotype-specific Ras GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res., 2001, 61, 4425-31.
62. Shi, Y.; Gera, J.; Hsu, J.; Van Ness, B.; Lichtenstein, A. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells. Mol. Cancer Ther., 2003, 2, 563-72.
63. Lebowitz, P.F.; Sakamuro, D.; Prendergast, G.C. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res., 1997, 57, 708-13.
64. Lobell, R.B.; Omer, C.A.; Abrams, M.T.; Bhimnathwala, H.G.; Brucker, M.J.; Buser, C.A.; Davide, J.P.; deSolms, S.J.; Dinsmore, C.J.; Ellis-Hutchings, M.S.; Kral, A.M.; Liu, D.; Lumma, W.C.; Machotka, S.V.; Rands, E.; Williams, T.M.; Graham, S.L.; Hartman, G.D.; Oliff, A.I.; Heimbrook, D.C.; Kohl, N.E. Evaluation of farnesyl: protein transferase and geranylgeranyl:protein transferase inhibitors combinations in preclinical models. Cancer Res., 2001, 61, 8758-68.
65. Crespo, N.C.; Ohkanda, J.; Yen, T.J.; Hamilton, A.D.; Sebti, S.M. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J. Biol. Chem., 2001, 276, 16161-67.
66. Ashar, H.R.; James, L.; Gray, K.; Car, D.; Black, S.; Armstrong, L.; Bishop, W.R.; Kirschmeier, P. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem., 2000, 275, 30451-57.
67. Kamasani, U.; Liu, A.X.; Prendergast, G.C. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol. Ther., 2003, 2, 273-80.
68. Crul, M.; de Klerk, G.J.; Beijnen, J.H.; Schellens, J. Ras biochemistry and farnesyl transferase inhibitors: A literature survey. Anticancer Drugs, 2001, 12, 163-84.
69. Rowinsky, E.K.; Windle, J.J.; VonHoff, D.D. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J. Clin. Oncol., 1999, 17, 3631-3652.
70. Patel, D.V.; Schmidt, R.J.; Biller, S.A.; Gordon, E.M.; Robinson, S.S.; Manne, V. Farnesyl diphosphate-based inhibitors of Ras farnesyl protein transferase. J. Med. Chem., 1995, 38, 2906-21.
71. Symons, M. The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Curr. Opin. Biotechnol., 1995, 6, 668-774.
72. Brown, M.S.; Goldstein, J.L.; Paris, K.J.; Burnier, J.P.; Marsters, J.C. Tetrapeptide inhibitors of protein farnesyltransferase: Aminoterminal substitution in phenylalanine-containing tetrapeptides restores farnesylation. Proc. Natl. Acad. Sci. USA, 1992, 89, 8313-16.
73. Sepp-Lorenzino, L.; Ma, Z.; Rands, E.; Kohl, N. E.; Gibbs, J.B.; Oliff, A.; Rosen, N. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res., 1995, 55, 5302-309.
74. Khol, N.E.; Omer, C.A.; Conner, M.W.; Anthony, N.J.; Davide, J.P.; DeSolms, S.J.; Giuliani, E.; Gomez, R.P.; Graham, S.L.; Hamilton, K. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1995, 1, 792-97.
75. Qian, Y.; Blaskovich, M. A.; Saleem, M.; Seong, C.M.; Wathen, S.P.; Hamilton, A.D.; Sebti, S.M. Design and structural requirements of potent peptidomimetics inhibitors of p21Ras farnesyltransferase. J. Biol. Chem., 1994, 269, 12410-13.
76. Skrzat, S.; Angibaud, P.; Venet, M.; Sanz, G.; Bowden, C.; End, D.W. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumour activity. Proc. Am. Assoc. Cancer Res., 1998, 39, 317.
77. End, E.; Skrzat, S G.; Devine, A.; Angibaud, P.; Venet, M.; Saz, G.; Bowden, C. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): Biochemical and cellular effects in H-ras and K-ras dominant systems. Proc. Am. Assoc. Cancer Res., 1998, 39, 269.
78. Smets, G.; van Eyck, N.; Devine, A.; Bowden, C.; Wouters, W.; End, D.W. R115777, a selectice farnesyl protein transferase inhibitor (FTI), induces predominantly apoptotic activity in C32 melanoma tumor xenografts. Proc. Am. Assoc. Cancer Res., 1999, 40, 522.
79. Bishop, W.R.; Bond, R.; Petrin, J.; Wang, L.; Patton, R.; Doll, R.; Njoroge, G.; Catino, J.; Schwartz, J.; Windsor, W.; Syto, R.; Schwartz, J.; Carr, D.; James, L.; Kirschmeier, P. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells. J. Biol. Chem., 1995, 270, 30611-18.
80. Liu, M.; Bryant, M.S.; Chen, J.; Lee, S.; Yaremko, B.; Li, Z.; Dell, J.; Lipari, P.; Malkowski, M.; Prioli, N.; Rossman, R.R.; Korfmacher, W.A.; Nomeir, A.A.; Lin, C.C.; Mallams, A.K.; Doll, R.J.; Catino, J.J.; Girijavallabhan, V.M.; Kirschmeier, P.; Bishop, W.R. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Cancer Chemother. Pharmacol., 1999, 43, 50-58.
81. Liu, M.; Lee, S.; Yaremko, B.; Chen, J.; Dell, J.; Nielsen, L.; Lipari, P.; Ferrari, E.; Malkowski, M.; Bryant, M.S.; Njoroge, F.G.; Traveras, A.G.; Doll, R.J.; Kirschmeier, P.; Nomeir, A.A.; Kelly, J.; Remiszewski, S.; Mallams, A.K.; Afonso, A.; Hollinger, F.P.; Cooper, A.B.; Liu, Y.; Rane, D.; Girijavallabhan, V.; Ganguly, A.K.; Bishop, W.R. SCH 66336, an orally bioavailable tricyclic farnesyl protein transferase inhibitor, demonstrates broad and potent in-vivo antitumor activity. Proc. Am. Assoc. Cancer Res., 1998, 39, 270.
82. Liu, M.; Bryant, M.S.; Chen, J.; Lee, S.; Yaremko, B.; Lipari, P.; Malkowski, M.; Ferrari, E.; Nielsen, L.; Prioli, N.; Dell, J.; Sinha, D.; Syed, J.; Korfmacher, W.A.; Nomeir, A.A.; Lin, C.C.; Wang, L.; Taveras, A.G.; Doll, R..J.; Njoroge, F.G.; Mallams, A.K.; Remiszewski, S.; Catino, J.J.; Girijavallabhan, V.M.; Bishop, W.R. Tumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase in human tumor xenograft models in wap-ras transgenic mice. Cancer Res., 1998, 58, 4947-56.
83. Mallams, A.K.; Njoroge, F.G.; Doll, R.J.; Snow, M.E; Kaminski, J.J.; Rossman, R.R.; Vibulbhan, B.; Bishop, W.R.; Kirschmeier, P.; Liu, M.; Bryant, M.S.; Alvarez, C.; Carr, D.; James, L.; King, I.; Li, Z.; Lin, C.C.; Nardo, C.; Petrin, J.; Remiszewski, S.W.; Taveras, A.G.; Wang, S.; Wong, J.; Catino, J.; Girijavallabhan, V.; Ganguly, A.K. Antitumor 8-chlorobenzocycloheptapyridines: A new class of selective, nonpeptidic, nonsulfhydryl inhibitors of Ras farnesylation. Bioorg. Med. Chem., 1997, 5, 93-99.
84. Njoroge, F.G.; Doll, R.J.; Vibulbhan, B.; Alvarez, C.S.; Bishop, W.R.; Petrin, J.; Kirschmeier, P.; Carruthers, N.I.; Wong, J.K.; Albanese, M.M.; Piwinski, J.J.; Catino, J.; Girijavallabhan, V.; Ganguly, A.K. Discovery of novel nonpeptidic tricyclic inhibitors of Ras farnesyl protein transferase. Bioorg. Med. Chem., 1997, 5, 101-13.
85. Njoroge, F.; Vibulbhan, B.; Rane, D.; Bishop, W.R.; Petrin, J.; Patton, R.; Bryant, M.S.; Chen, K.; Nomeir, A.A.; Lin, C.; Liu, M.; King, I.; Chen, J.; Lee, S.; Yaremko, B.; Dell, J.; Lipari, P.; Malkowski, M.; Li, Z.; Catino, J.; Doll, R.J.; Girijavallabhan, V.; Ganguli, A.K. Structure activity relationship of 3-substituted n-(pyridinylacetyl)-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1, 2-b]pyridine-11-ylidene)-piperidine inhibitors of farnesyl protein transferase: design and synthesis of in vivo active antitumor compounds. J. Med. Chem., 1997, 40, 4290-301.
86. Manne, V.; Yan, N.; Carboni, J.M.; Tuomari, A.V.; Ricca, C.S.; Brown, J.G.; Andahazy, M.L.; Schmidt, R.J.; Patel, D.; Zahler, R. Bisubstrate inhibitors of farnesyl transferase: A novel class of specific inhibitors of Ras transformed cells. Oncogene, 1995, 10, 1763-1779.
87. Yan, N.; Ricca, C.; Fletcher, J.; Glover, T.; Seizinger, B.R.; Manne, V. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res., 1995, 55, 3569-75.
88. Hara, M.; Akasaka, K.; Akinaga, S.; Okabe, M.; Nakano, H.; Gomez, R.; Wood, D.; Uh, M.; Tamanoi, F. Identification of Ras farnesyl transferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA, 1993, 90, 2281-85.
89. Singh, S.B.; Zinc, D.L.; Liesch, J.M.; Goetz, M.A.; Jenkins, R.G.; Nallin-Omstead, M.; Silverman, K.C.; Bills, G.F.; Mosley, R.T.; Gibbs, J.B.; Albers-Schonberg, G.; Lingham, R.B. Isolation and structure of chaetomelic acids a and b from chaetomell acutiseta: farnesyl pyrophosphate mimic inhibitors of Ras farnesyl-protein transferase. Tetrahedron, 1993, 49, 5917-26.
90. Singh, S.B.; Liesch, J.M.; Lingham, R.B.; Silverman, K.C.; Sigmund, J.M.; Goetz, M.A. Structure, chemistry, and biology of actinoplanic acids: potent inhibitors of Ras farnesyl protein transferase. J. Org. Chem., 1995, 60, 7896-901.
91. Singh, S.B.; Jones, E.T.; Goetz, M.A.; Bills, G.F.; Nallin-Omstead, M.; Jenkins, R.G.; Lingham, R.B.; Silverman, K.C.; Gibbs, J.G. Fusidieno: A novel inhibitor of Ras farnesyl-protein transferase from fusidium griseum. Tetrahedron Lett., 1994, 35, 4693-96.
92. Singh, S.B.; Zink, D.L.; Bills, G.F.; Jenkins, R.G.; Silverman, K.C.; Lingham, R.B. Cylindrol A: A novel inhibitor of Ras farnesyl-protein transferase from cylindrocarpon lucidum. Tetrahedron Lett., 1995, 36, 4935-38.
93. Tamanoi, F.; Mitsuzawa, H. Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. Methods Enzymol., 1995, 255, 82-91.
94. Kainuma, O.; Asano, T.; Hasegawa, M.; Kenmochi, T.; Nakagohri, T.; Tokoro, Y.; Isono, K. Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas, 1997, 15, 379-83.
95. Eskens, F.A.L.M.; Stoter, G.; Verweij, J. Farnesyl transferase inhibitors: current developments and future perspectives. Cancer Treat. Rev., 2000, 26, 319-332.
96. Yasui, W.; Nishiyama, M.; Tsuruo, T.; Tahara, E. Molecular targeting therapy for cancer: the twelfth international symposium of the hiroshima cancer seminar, november 2002. Cancer Sci., 2003, 94, 221-23.
97. Zujewski, J.; Horak, I.D.; Bol, C.J.; Woestenborghs, R.; Bowden, C.; End, D.W.; Piotrovsky, V.K.; Chiao, J.; Belly, R.T.; Todd, A.; Kopp, W.C.; Kohler, D.R.; Chow, C.; Noone, M.; Hakim, F.T.; Larkin, G.; Gress, R.E.; Nussenblatt, R.B.; Kremer, A.B.; Cowan, K.H. Phase I and pharmacokinetic study of farnesyl transferase inhibitor R1157777 in advanced cancer. J. Clin. Oncol., 2000, 18, 927-41.
98. Schellens, J.H.; de Klerk, G.; Swart, M.; Palmer, P.A.; Bol, C.J.; van't Veer, L.J.; Tan, S.; de Gast, G.C.; Beijnen, J.H.; ten Bokkel Huinink, W.W. Phase I and pharmacologic study with the novel farnesyl transferase inhibitor (FTI) R115777. Proc. Am. Soc. Clin. Oncol., 2000, 19, 184a.
99. Crul, M.; de Klerk, G.J.; Swart, M.; van't Veer, L.J.; de Jong, D.; Boerrigter, L.; Palmer, P.A.; Bol, C.J.; Tan, H.; de Gast, G.C.; Beijnen, J.H.; Schellens, J.H. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol., 2002, 20, 2726-35.
100. Punt, C.J.; van Maanen, L.; Bol, C.J.; Seifert W.F.; Wagener D.J. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs, 2001, 12, 193-197.
101. Johnston, S.R.; Hickish, T.; Ellis, P.; Houston, S.; Kelland, L.; Dowsett, M.; Salter, J.; Michiels, B.; Perez-Ruixo, J.J.; Palmer, P.; Howes, A. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol., 2003, 21, 2492-99.
102. Kurzrock, R.; Kantarjian, H.M.; Cortes, J.E.; Singhania, N.; Thomas, D.A.; Wilson, E.F.; Wright, J.J.; Freireich, E.J.; Talpaz, M.; Sebti, S.M. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase I setting. Blood, 2003, 102, 4527-34.
103. Rao, S.; Cunningham, D.; de Gramont, A.; Scheithauer, W.; Smakal, M.; Humblet, Y.; Kourteva, G.; Iveson, T.; Andre, T.; Dostalova, J.; Illes, A.; Belly, R.; Perez-Ruixo, J.J.; Park, Y.C.; Palmer, P.A. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol., 2004, 22, 3950-57.
104. Cunningham, D.; de Gramont, A.; Scheithauser, W.; Smakal, M.; Humblet, Y.; Kurteva, G.; Iveson, T.; Andre, T.; Dostalova, J.; Illes, A.; Jia, X.; Palmer, P. Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra ™) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 2002, 21, 502.
105. Van Cutsem, E.; Karasek, P.; Oettle, H.; Vervenne, W.L.; Szawlowski, A.; Schoffski, P.; Post, S.; Neumann, H.; Safran, H.; Humblet, Y.; van de Velde, H.; Ma, Y.; Von Hoff, D. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol., 2002, 21, 517.
106. Harousseau, J.L. Farnesyltransferase inihibitors in hematologic malignancies. Blood Rev., 2007, 21(4), 173-82.
107. Karp, J.E.; Lancet, J.E.; Kaufmann, S.H.; End, D.W.; Wright, J.J.; Bol, K.; Horak, I.; Tidwell, M.L.; Liesveld, J.; Kottke, T.J.; Ange, D.; Buddharaju, L.; Gojo, I.; Highsmith, W.E.; Belly, R.T.; Hohl, R.J.; Rybak, M.E.; Thibault, A.; Rosenblatt, J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical laboratory correlative trial. Blood, 2001, 97, 3361-69.
108. Field, K.A.; Charoenthongtrakul, S.; Bishop, J.M.; Refaeli, Y. Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas. Mol. Cancer, 2008, 7, 39-51.
109. Awada, A.; Eskens, F.A.; Piccart, M.; Cutler, D.L.; van der Gaast, A.; Bleiberg, H.; Wanders, J.; Faber, M.N.; Statkevich, P.; Fumoleau, P.; Verweij, J. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur. J. Cancer, 2002, 38, 2272-78.
110. Eskens, F.A.; Awada, A.; Cutler, D.L.; de Jonge, M.J.;Luyten, G.P.; Faber, M.N.; Statkenich, P.; Sparreboom, A.; Verweij, J.; Hananske, A.R.; Piccart, M. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J. Clin. Oncol., 2001, 19, 1167-75.
111. Adjei, A.A.; Erlichman, C.; Davis, J.N.; Reid, J.; Sloan, J.; Statkevich, P.; Zhu, Y.; Randolph, M.; Henry, P.; Goldberg, R.; Hanson, L.; Alberts, S.; Cutler, D.; Scott, K. A phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer. Proc. Am. Soc. Clin. Oncol., 1999, 18, 156a.
112. Adjei, A.A.; Erlichman, C.; Davis, J.N.; Cutler, D.L.; Sloan, J.A.; Marks, R.S.; Hanson, L.J.; Svingen, P.A.; Atherton, P.; Bishop, W.R.; Kirschmeier, P.; Kaufmann, S.H. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res., 2000, 60, 1871-77.
113. Winquist, E.; Moore, M.J.; Chi, K.N.; Ernst, D.S.; Hirte, H.; North, S.; Powers, J.; Walsh, W.; Boucher, T.; Patton, R.; Seymour, L. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol. Oncol., 2005, 23, 143-49.
114. Winquist, E.; Moore, M.J.; Chi, K.; Ernst, S.; Hirte, H.; Iscoe, N.; Venner, P.; Huan, S.; Powers, J.; Seymour, L.; Boucher, T. NCIC CTG IND.128: A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol., 2001, 20, 785.
115. Ravoet, C.; Mineur, P.; Robin, V.; Debusscher, L.; Bosly, A.; Andre, M.; El-Housni, H.; Soree, A.; Bron, D.; Martiat, P. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: A phase II study. Ann. Hematol., 2008, 87(11), 881-85.
116. Camacho, L.H.; Soignet, S.; Pezzuli, S.; Canales, C.; Aghajanian, C.; Spriggs, D.S.; Damle, B.; Sonnichsen, D. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol., 2001, 20, 311.
117. Ryan, D.P.; Eder, J.P.; Puchlaski, T.; Seiden, M.V.; Lynch, T.J.; Fuchs, C.S.; Amrein, P.C.; Sonnichsen, D.; Supko, J.G.; Clark, J.W. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin. Cancer Res., 2004, 10, 2222-30.
118. Papadimitrakopoulou, V.; Agelaki, S.; Tran, H.T.; Kies, M.; Gagel, R.; Zinner, R.; Kim, E.; Ayers, G.; Wright, J.; Khuri, F. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. Clin. Cancer Res., 2005, 11, 4151-4159.
119. End, D.W.; Smets, G.; Todd, A.V.; Applegate, T.L.; Fuery, C.J.; Angibaud, P.; Venet, M.; Sanz, G.; Poignet, H.; Skrzat, S.; Devine, A.; Wouters, W.; Bowden, C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res., 2001, 61, 131-37.
120. Sun, J.; Blaskovich, M.A.; Knowles, D.; Qian, Y.; Ohkanda, J.; Bailey, R.D.; Hamilton, A.D.; Sebti, S.M. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res., 1999, 59, 4919-26.
121. Adjei, A.A. Farnesyltransferase inhibitors. Updat Cancer Ther., 2006, 1, 17-23.
122. Moasser, M.M.; Sepp-Lorenzino, L.; Kohl, N.E.; Oliff, A.; Balog, A.; Su, D.S.; Danishefsky, S.J.; Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epithelones. Proc. Natl. Acad. Sci. USA, 1998, 95, 1369-74.
123. Khuri, F.R.; Glisson, B.S.; Kim, E.S.; Statkevich, P.; Thall, P.F.; Meyers, M.L.; Herbst, R.S.; Munden, R.F.; Tendler, C.; Zhu, Y.; Bangert, S.; Thompson, E.; Lu, C.; Wang, X.M.; Shin, D.M.; Kies, M.S.; Papadimitrakopoulou, V.; Fossella, F.V.; Kirschmeier, P.; Bishop, W.R.; Hong, W.K. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin. Cancer Res., 2004, 10, 2968-76.
124. Sharma, S.; Britten, C.; Spriggs, D.; Rosen, N.; Soignet, S.; Pezzulli, S.; Patnik, A.; Kher, U.; Arena, C.; Deutsch, P.; Yao, S.; Rowinsky, E. A phase I and PK study of farnesyl transferase inhibitor L-778,123 administered as a seven day continuous infusion in combination with paclitaxel. Proc. Am. Soc. Clin. Oncol., 2000, 19, 719.
125. Khuri, F.R.; Glisson, B.S.; Meyers, M.L.; Herbst, R.S.; Thall, P.F.; Munden, R.F.; Bangert, S.; Cascino, M.; Blumenschein, G.; Pisters, K.; Hong, W.K. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. Proc. Am. Soc. Clin. Oncol. 2000, 19, 799.
126. Shi, B.; Gurnani, M.; Yaremko, B.; Lee, S.; Chen, J.; Lipari, P.; Ferrari, E.; Malkowski, M.; Liu, M.; Gerald Haijan, G.; Nielsen, L.L. Enhanced efficacy of the farnesyl protein transferase inhibitor SCH 66336 in combination with paclitaxel. Proc. Am. Assoc. Cancer Res., 1999, 40, 524.
127. Druker, B.J. Overcoming resistance to imatinib by combining targeted agents. Mol. Cancer Ther., 2003, 2(3), 225-26.
128. Theodore, C.; Geoffrois, L.; Vermorken, J.B.; Caponigro, F.; Fiedler, W.; Chollet, P.; Ravaud, A.; Peters, G.J.; de Balincourt, C.; Lacombe, D.; Fumoleau, P. Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur. J. Cancer, 2005, 41, 1150-57.
129. Hurwitz, H.I.; Amado, R.; Prager, D.; Hecht, J.R.; Cohen, D.P.; Conway, D.; Kadib, L.; Mayers, A.; Calzetta, A.; Statkevich, P.; Cutler, D.L.; Rosen, L.S. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers. Proc. Am. Soc. Clin. Oncol., 2000, 19, 717.
130. Van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W.L.; Szawlowski, A.; Schoffski, P.; Post, S.; Verslype, C.; Neumann, H.; Safran, H.; Humblet, Y.; Perez Ruixo, J.; Ma, Y.; Von Hoff, D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol., 2004, 22, 1430-38.
131. Patnik, A.; Eckhardt, S.; Itzbicka, E. A phase I and pharmacokinetic study of the farnesytransferase inhibitor, R115777 in combination with gemcitabine. Proc. Am. Soc. Clin. Oncol., 2000, 19, 689.
132. Skrzat, S.; Bowden, C.; End, D. Interaction of the farnesyl protein transferase inhibitor (FTI) R115777 with cytotoxic chemotherapeutics in vitro and in vivo. Proc. Am. Assoc. Cancer Res., 1999, 40, 523.
133. Verslype, C.; Van Steenbergen, W.; Humblet, Y. Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777. Proc. Am. Soc. Clin. Oncol., 2001, 20, 681.
134. Peeters, M.; VanCustem, E.; Marse, H.; Palmer, P.; Walraven, V.; Willems, L. Phase I combination trial of the farnesyl transferase inhibitor (FTI) R115777 with a 5FU/LV regimen in advanced colorectal and pancreatic cancer. Proc. Am. Soc. Clin. Oncol., 1999, 18, 223a.
135. Cortes, J.; Garcia-Manero, G.; O'Brien, S. A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed in therapy. Blood, 2004, 104, 1011.
136. Bailey, H.H.; Marnocha, R.; Arzoomanian, R.; Alberti, D.; Binger, K; Volkman, J.; Feierabend, C.; Ellingen, S.; Black, S.; Hampton, K.; Cooper, M.; Hott, T.; Wilding, G. Phase I trial of weekly paclitaxel and BMS214662 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 2001, 20, 314.
137. Dy, G.K.; Bruzek, L.M.; Croghan, G.A.; Mandrekar, S.; Erlichman, C.; Peethambaram, P.; Pitot, H.C.; Hanson, L.J.; Reid, J.M.; Furth, A.; Cheng, S.; Martell, R.E.; Kaufmann, S.H.; Adjei, A.A. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662 in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin. Cancer Res., 2005, 11, 1877-83.
138. McKenna, W.G.; Weiss, M.C.; Endlich, B.; Ling, C.C.; Bakanauskas, V.J.; Kelsten, M.L.; Muschel, R.J. Synergistic effect of the v-myc oncogene with H-Ras on radioresistance. Cancer Res., 1990, 50, 97-102.
139. Kim, I.A.; Fernandes, A.T.; Gupta, A.K.; McKenna, W.G.; Bernhard, E.J. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev., 2004, 23, 227-36.
140. Cengel, K.A.; McKenna, W.G. Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model. Crit. Rev. Oncol. Hematol., 2005, 55, 103-16.
141. Hahn, S.M.; Bernhard, E.J.; Regine, W.; Mohiuddin, M.; Haller, D.G.; Stevenson, J.P.; Smith, D.; Pramanik, B.; Tepper, J.; De-Laney, T.F.; Kiel, K.D.; Morrison, B.; Deutsch, P.; Muschel, R.J.; McKenna, W.G. A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
142. Hahn, S.M.; Kiel, K.; Morrison, B.W.; Mohiuddin, M.M.; Thomas, D.; Smith, D.; Brown, R.; Brown, R.; Pramanik, B.; Kher, U.; Deutsch, P.; McKenna, W.G. Phase I trial of the farnesyl transferase inhibitor L-778123 in combination with radiotherapy. Proc. Am. Soc. Clin. Oncol., 2000, 19, 906.